[go: up one dir, main page]

RS20050945A - Novel pyrrolodihydroisoquinolines useful in the treatment of cancer - Google Patents

Novel pyrrolodihydroisoquinolines useful in the treatment of cancer

Info

Publication number
RS20050945A
RS20050945A YUP-2005/0945A YUP20050945A RS20050945A RS 20050945 A RS20050945 A RS 20050945A YU P20050945 A YUP20050945 A YU P20050945A RS 20050945 A RS20050945 A RS 20050945A
Authority
RS
Serbia
Prior art keywords
novel
cancer
pyrrolodihydroisoquinolines
useful
treatment
Prior art date
Application number
YUP-2005/0945A
Other languages
English (en)
Inventor
Paola Ciapetti
Camille Georges Wermuth
Volker Gekeler
Thomas Baer
Matthias Vennemann
Jurgen Braunger
Petra Gimmnich
Jean-Marie Contreras
Original Assignee
Altana Pharma Ag.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag., filed Critical Altana Pharma Ag.,
Publication of RS20050945A publication Critical patent/RS20050945A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Pronalazak se odnosi na nove derivate pirolodihidroizohinolina, koji su efikasni inhibitori ćelijske (hiper)proliferacije i/ili izazivača apoptoze u ćelijama kancera.
YUP-2005/0945A 2003-06-30 2004-06-30 Novel pyrrolodihydroisoquinolines useful in the treatment of cancer RS20050945A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03014424 2003-06-30
PCT/EP2004/051315 WO2005003130A1 (en) 2003-06-30 2004-06-30 Novel pyrrolodihydroisoquinolines useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
RS20050945A true RS20050945A (en) 2008-06-05

Family

ID=33560746

Family Applications (2)

Application Number Title Priority Date Filing Date
YUP-2005/0946A RS20050946A (en) 2003-06-30 2004-06-30 Pyrrolodihydroisoquinolines as pde10 inhibitors
YUP-2005/0945A RS20050945A (en) 2003-06-30 2004-06-30 Novel pyrrolodihydroisoquinolines useful in the treatment of cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
YUP-2005/0946A RS20050946A (en) 2003-06-30 2004-06-30 Pyrrolodihydroisoquinolines as pde10 inhibitors

Country Status (22)

Country Link
US (2) US20060148840A1 (sr)
EP (2) EP1641794A1 (sr)
JP (2) JP2009513494A (sr)
KR (1) KR20060030483A (sr)
CN (2) CN1809565A (sr)
AR (2) AR044956A1 (sr)
AT (1) ATE478868T1 (sr)
AU (2) AU2004253690B2 (sr)
BR (1) BRPI0411897A (sr)
CA (2) CA2530316A1 (sr)
DE (1) DE602004028827D1 (sr)
EA (1) EA012110B1 (sr)
IL (1) IL171997A0 (sr)
IS (1) IS8238A (sr)
MX (2) MXPA05013553A (sr)
NO (1) NO20060202L (sr)
NZ (1) NZ544591A (sr)
RS (2) RS20050946A (sr)
TW (2) TW200510413A (sr)
UA (1) UA86591C2 (sr)
WO (2) WO2005003129A1 (sr)
ZA (2) ZA200509265B (sr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2530316A1 (en) * 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolodihydroisoquinolines as pde10 inhibitors
ATE430148T1 (de) * 2005-01-12 2009-05-15 Nycomed Gmbh Neue pyrrolodihydroisochinoline als pde10- inhibitoren
CA2595075A1 (en) * 2005-01-12 2006-07-20 Matthias Vennemann Pyrrolodihydroisoquinolines as antiproliferative agents
US20100179131A1 (en) 2006-09-07 2010-07-15 Nycomed Gmbh Combination treatment for diabetes mellitus
CN101742906A (zh) 2007-06-04 2010-06-16 本古里安大学内盖夫研究发展局 三芳基化合物和包含它们的组合物
US7858620B2 (en) 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
TW200918519A (en) * 2007-09-19 2009-05-01 Lundbeck & Co As H Cyanoisoquinoline
TW200944523A (en) 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
WO2009108383A2 (en) 2008-02-29 2009-09-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
TWI461426B (zh) * 2009-05-27 2014-11-21 Merck Sharp & Dohme （二氫）咪唑並異〔５，１－ａ〕喹啉類
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
DE102010042833B4 (de) 2010-10-22 2018-11-08 Helmholtz-Zentrum Dresden - Rossendorf E.V. Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
JP2014510055A (ja) 2011-02-18 2014-04-24 アラーガン インコーポレイテッド ホスホジエステラーゼ１０（ｐｄｅ１０ａ）阻害剤としての置換６，７−ジアルコキシ−３−イソキノリノール誘導体
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2013045607A1 (en) 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
WO2013050527A1 (en) 2011-10-05 2013-04-11 H. Lundbeck A/S Quinazoline derivatives as pde10a enzyme inhibitors
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
CN103059029B (zh) * 2012-12-28 2014-12-10 塔里木大学 一种六氢吡咯[2,3]并吲哚类化合物及其制备方法和在杀菌活性中的应用
SI3027613T1 (sl) * 2013-07-25 2018-10-30 Uniwersytet Jagiellonski Derivati pirolokvinolina kot 5-HT6 antagonisti, postopek priprave in uporabe le-teh
JP6657101B2 (ja) 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ 糖尿病及びそれから生じる疾患合併症の治療のための化合物
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CA2981791A1 (en) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE690792A (sr) * 1966-12-07 1967-05-16
DE3401018A1 (de) * 1984-01-13 1985-07-18 Boehringer Ingelheim KG, 6507 Ingelheim Verfahren zur herstellung von 5,6-dihydro-pyrrolo(2,1-a)isochinolinen
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2004517843A (ja) * 2000-12-13 2004-06-17 バイエル アクチェンゲゼルシャフト ピロロ［２．１−ａ］ジヒドロイソキノリンおよびホスホジエステラーゼ１０ａ阻害薬としてのその使用
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
US20030018047A1 (en) * 2001-04-20 2003-01-23 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) * 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
DE10130151A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Neue Verwendung für PDE 10A-Inhibitoren
WO2003014116A1 (en) * 2001-08-06 2003-02-20 Bayer Corporation Pyrrolo[2.1-a]isoquinoline derivatives
WO2003014115A1 (en) * 2001-08-06 2003-02-20 Bayer Aktiengesellschaft 3-substituted pyrrolo (2.1-a) isoquinoline derivatives
WO2003051877A1 (en) * 2001-12-18 2003-06-26 Bayer Corporation 2-substituted pyrrolo[2.1-a]isoquinolines against cancer
CA2530316A1 (en) * 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolodihydroisoquinolines as pde10 inhibitors
CA2595075A1 (en) * 2005-01-12 2006-07-20 Matthias Vennemann Pyrrolodihydroisoquinolines as antiproliferative agents
ATE430148T1 (de) * 2005-01-12 2009-05-15 Nycomed Gmbh Neue pyrrolodihydroisochinoline als pde10- inhibitoren

Also Published As

Publication number Publication date
US20060148840A1 (en) 2006-07-06
EP1641794A1 (en) 2006-04-05
JP2009513495A (ja) 2009-04-02
MXPA05013553A (es) 2006-03-09
TW200510413A (en) 2005-03-16
EP1641792B1 (en) 2010-08-25
NO20060202L (no) 2006-01-13
JP2009513494A (ja) 2009-04-02
AR045696A1 (es) 2005-11-09
CA2530317A1 (en) 2005-01-13
AU2004253694A1 (en) 2005-01-13
ZA200509265B (en) 2006-10-25
RS20050946A (en) 2008-06-05
MXPA05013822A (es) 2006-02-28
CA2530316A1 (en) 2005-01-13
IL171997A0 (en) 2011-08-01
US20060148838A1 (en) 2006-07-06
AU2004253690A1 (en) 2005-01-13
NZ544591A (en) 2009-07-31
ATE478868T1 (de) 2010-09-15
EP1641792A1 (en) 2006-04-05
WO2005003129A1 (en) 2005-01-13
DE602004028827D1 (de) 2010-10-07
UA86591C2 (ru) 2009-05-12
IS8238A (is) 2006-01-18
ZA200509267B (en) 2006-08-30
WO2005003130A1 (en) 2005-01-13
CN1809565A (zh) 2006-07-26
KR20060030483A (ko) 2006-04-10
EA200501928A1 (ru) 2006-12-29
AU2004253690B2 (en) 2010-03-25
CN1809564A (zh) 2006-07-26
BRPI0411897A (pt) 2006-08-29
EA012110B1 (ru) 2009-08-28
TW200510407A (en) 2005-03-16
AR044956A1 (es) 2005-10-12

Similar Documents

Publication Publication Date Title
MXPA05013822A (es) Pirrolodihidroisoquinolinas utiles en el tratamiento del cancer.
IL258880A (en) Diarylhydantoin compounds
NL301145I2 (nl) Tirbanibulin
TW200612918A (en) Lonidamine analogs
SG148864A1 (en) Methods of treating cancer and related methods
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
WO2004063355A3 (en) Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
DK1261367T3 (da) Anvendelse af interleukin-6-antagonister til behandling af östrogenafhængige tumorer
ATE425982T1 (de) Thienopyrimidin-derivate als kaliumkanal- inhibitoren
WO2006075012A3 (en) Pyrrolodihydroisoquinolines as antiproliferative agents
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
TW200508233A (en) Chk-1 inhibitors
DE602005021681D1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
TW200605885A (en) Multicyclic lonidamine analogs
DE50311665D1 (de) Guanidinophenylalanin-verbindungen als urokinase-inhibitoren
WO2005082357A8 (en) Use of beta-lapachone for treating hematologic tumors
MXPA03002494A (es) Metodo para reducir toxicidad de quimio terapias combinadas.
DK1757283T3 (da) Antitumorvirkningsforstærker, antitumor middel og fremgangsmåde til cancerterrapi
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
WO2005082353A3 (en) Use of beta-lapachone for treating or preventing cancer
WO2005048956A3 (en) Estradiol-related compounds and methods of use as anti-tumor agents
MX2022002607A (es) Metodos de tratamiento.